We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. markets closed

Geron Corporation (GERN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
3.6400-0.1300 (-3.45%)
At close: 04:00PM EDT
3.6988 +0.06 (+1.62%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Bollinger Bands

Bollinger Bands

Performance Outlook
Previous Close3.7700
Open3.7900
Bid3.6300 x 3700
Ask3.6600 x 7400
Day's Range3.5800 - 4.0500
52 Week Range1.6400 - 4.0500
Volume22,367,781
Avg. Volume12,365,124
Market Cap2.141B
Beta (5Y Monthly)0.61
PE Ratio (TTM)N/A
EPS (TTM)-0.3200
Earnings DateMay 09, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.08
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GERN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Geron Corporation
    DVAX: What does Argus have to say about DVAX?DYNAVAX TECHNOLOGIES CORP has an Investment Rating of SELL; a target price of $10.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • Simply Wall St.

    Geron Corporation (NASDAQ:GERN) Is Expected To Breakeven In The Near Future

    We feel now is a pretty good time to analyse Geron Corporation's ( NASDAQ:GERN ) business as it appears the company may...

  • Business Wire

    Geron to Participate at Upcoming Investor Conferences in April

    FOSTER CITY, Calif., April 03, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences:

  • BioPharma Dive

    5 FDA decisions to watch in the second quarter

    The FDA could soon expand use of two multiple myeloma cell therapies as well as a top-selling medicine from Sanofi and Regeneron, while Pfizer’s years of gene therapy work might finally pay dividends.

  • Zacks

    Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

    Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.

  • Business Wire

    Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

    FOSTER CITY, Calif., March 19, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of $3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock. The pre-funded warrants are being sold at a price of $2.999 per pre-funded warrant. All of the securities in the offering are to be sold by Geron. The offering included

  • Yahoo Finance Video

    Geron, Madrigal Pharmaceuticals jump on good news from FDA

    Shares of both Geron (GERN) and Madrigal Pharmaceuticals (MDGL) are soaring after receiving positive news from the Food and Drug Administration. For Geron, an FDA advisory panel backed its blood disorder treatment. For Madrigal, the FDA approved its treatment for a liver disease known as nonalcoholic steatohepatitis, or NASH. Yahoo Finance's Josh Lipton and Julie Hyman discuss the stocks' reaction in the video above. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Stephanie Mikulich.

  • The Wall Street Journal

    Stocks to Watch Friday: Adobe, Ulta, Fisker

    [**Adobe (ADBE)**](https://www.wsj.com/market-data/quotes/ADBE): The software company's latest results topped forecasts, but guidance for its current quarter [disappointed investors](https://www.wsj.com/livecoverage/stock-market-today-dow-jones-03-15-2024/card/adobe-reports-solid-earnings-but-stock-sinks-after-outlook-underwhelms-investors-fg7wmoXAIxD5cpqyO7v8).

  • Zacks

    Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up

    Geron's (GERN) pipeline candidate, imetelstat, gets FDA Committee backing for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.

  • Benzinga

    Geron Stock Is Soaring After Hours: What's Going On?

    Geron Corp (NASDAQ:GERN) shares are soaring in Thursday's after-hours session after the company announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia. What Happened: After the market close on Thursday, Geron announced that ODAC voted 12 to two in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusio

  • Business Wire

    Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

    FOSTER CITY, Calif., March 14, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to 2 in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-inte